

IAP12 Rec'd PCT/PTO 24 AUG 2006

Attorney Docket No. BHC 041036

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: GIELEN-HÄRTWIG, et al.

Group No.:

Serial No.: [to be assigned] National Stage of: PCT/EP2005/001486

Examiner:

Filed: herewith

For: 1,4-Diaryl-Dihydropyrimidin-2-Ones and Their Use as Human Neutrophil Elastase Inhibitors

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as express mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: August 24, 2006


William F. Gray

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed within three months of the filing or nationalization of this application, or before the mailing date of the first Office action on the merits.

FEE PAYMENT


Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No. 31018

Telephone: (203) 812-2712

Date: August 24, 2006


William F. Gray
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Serial No.	Group Art Unit	Filing Date 08/24/2006	Atty. Docket No. BHC 041036
1 of 1		Applicant(s) GIELEN-HÄRTWIG, et al.			
INFORMATION DISCLOSURE CITATION					

FOREIGN PATENT DOCUMENTS								
Examiner initials*	Cite No. ¹	DOCUMENT NO.	DATE MM/DD/YY	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	F1	2003/053930	07/03/03	WO				
	F2	2004/024700	03/25/04	WO				

Examiner initials*	Cite No. ¹	OTHER REFERENCES (Including Author, Title, Publishing, <u>Volume</u> , Pages, (Year) etc.)
	R1	Ohmoto, et al., Development of Orally Active Nonpeptidic Inhibitors of Human Neutrophil Elastase; J. Med. Chem., 44, pp. 1268-1285 (2001)

EXAMINER	DATE CONSIDERED
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	